Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

All patients achieved hepatitis B surface antigen (HBsAg) clearance post-treatment. Result: The study enrolled 176 patients with chronic hepatitis B, with the median IFN treatment course of 35.23 ± 25 ...

Alpha-fetoprotein (AFP) was negative. Anti-HBV treatment of oral telbivudine 600 mg per day was initiated at the Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

At 72 weeks, IHCs in the treatment group were categorized into an HBsAg clearance group and an HBsAg persistence group. Differences in T lymphocyte subsets among these groups were compared ...

Peripheral blood T lymphocyte subsets were evaluated using flow cytometry at baseline, and at 12, 24, 48, and 72 weeks in both groups. At 72 weeks, IHCs in the treatment group were categorized into an ...

Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which makes brelovitug a potentially safe and highly efficacious ...

A functional cure is said to have been achieved if HBsAg is cleared from the blood and remains undetectable after stopping all treatment. In B-Clear, patients with low baseline HBsAg levels ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...